Ultimovacs
Be the first to follow this company
Ultimovacs is a Norwegian pharmaceutical company. The company's business focus is to develop immunotherapies for various cancer conditions. Research and development are based on a self-based technological platform, where the products are mainly further developed as vaccines. The largest presence is in Europe and North America. Ultimovacs was founded in 2011 and is headquartered in Oslo.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
Oslo Børs
ULTI
Daily low / high price
-
Market cap
-
Turnover
-
Volume
-
Financial calendar
Interim report
2024-05-07
Interim report
2024-08-21
Interim report
2024-11-06
Annual report
2025-02-13
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Gjelsten Holding AS | 18.9 % | 18.9 % |
Canica AS | 7.9 % | 7.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Ultimovacs ASA – Annual General Meeting held on April 18, 2024
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools